A PHASE 1/2, FIRST-IN-HUMAN, MULTICENTER, ASCENDING SINGLE-DOSE AND MULTI-DOSE STUDY TO ASSESS THE SAFETY OF DIAG723, A NOVEL BISPECIFIC ALK-1 AND BMPRII AGONIST ANTIBODY IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (DIAMOND TRIAL)

Registry ID

DIAG723-PT-CL-001

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

DIAGONAL THERAPEUTICS, INC.

Last update

2026-07-17

Conditions

• HEREDITARY HAEMORRHAGIC TELANGIECTASIA

Related clinical trials

• A PHASE 1/2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-PART STUDY OF THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE DOSE ALN-6400 IN ADULT HEALTHY VOLUNTEERS AND MULTIPLE DOSE ALN-6400 IN ADULT PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
• DOXYCYCLINE CROSSOVER TRIAL FOR HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

View on source registry